General World News

WALL STREET PAYDAY: 4 banks made a killing from Monday’s $20 billion in biotech deals

party celebration confetti

  • Biotech mergers and acquisitions are off to a hot start in 2018.
  • On Monday, French drugmaker Sanofi spent $11.6 billion to buy US hemophilia firm Bioverativ, and Celgene spent $9 billion on cancer specialist Juno Therapeutics.
  • Investment banks stand to make as much as $185 million in fees for advising on the deals.

Two major biotech acquisitions dropped on Monday: French drugmaker Sanofi spent $11.6 billion to buy US hemophilia firm Bioverativ, and Celgene spent $9 billion on cancer specialist Juno Therapeutics.

The more than $20 billion in pharma mergers and acquisitions means a windfall of as much as $185 million in read more >>>

Source:: BusinessInsider.Com